Aspiriant LLC Purchases 49 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aspiriant LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 387 shares of the biopharmaceutical company’s stock after buying an additional 49 shares during the quarter. Aspiriant LLC’s holdings in Regeneron Pharmaceuticals were worth $276,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in REGN. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $49,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on REGN shares. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Evercore ISI cut their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Royal Bank of Canada lowered their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Finally, Oppenheimer decreased their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $687.80 on Wednesday. The stock has a market cap of $75.58 billion, a P/E ratio of 17.02, a P/E/G ratio of 1.61 and a beta of 0.10. The business’s fifty day moving average is $735.72 and its 200 day moving average is $946.39. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.